David I Smith received his PhD in Biochemistry from the University of Wisconsin in 1978. He did post-doctoral research first at the Albert Einstein College of Medicine and then at the University of California, Irvine. His first faculty position was in the Department of Molecular Biology and Genetics at Wayne State University in Detroit. In 1996 he joined the Department of Laboratory Medicine and Pathology at the Mayo Clinic as a Professor. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. The goal of this Group is to analyze new technologies for their potential impact on basic research and the clinical translation of these results. His laboratory studies the common fragile sites which are regions of profound genomic instability found in all individuals. His group is also studying the various ways that human papillomavirus is involved in the development of different cancers. His group uses different next-generation sequencing technologies to analyze where HPV has integrated into the human genome in these different cancers and the resulting genomic disruptions caused by these integrations.
Oropharyngeal cancer, Long noncoding RNA.
Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.
Heart Disease Research ,Acupuncture & Electro-Therapeutics Research, Integrated Medicine .
Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Thus, Dr. Nowicky is invited as an Honorable Speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
Anticancer protonic therapy
Iris Lavon is currently the Associate Professor of Neurobiology; She is also the Head of Molecular Neuro-Oncology Laboratory, Neurology Department in Hadassah at Hebrew University Medical Center, Jerusalem, Israel.